Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01196936 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
A Phase 2 study of Breast Cancer, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 13
- Study locations
NCT01196936 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 84 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 13 study locations across 12 states.
The verdict
NCT01196936, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 13
- Study locations
Study Summary
Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells This phase IIb trial studies how well low-dose tamoxifen citrate works in reducing breast cancer risk in radiation-induced cancer survivors.
Conditions Studied
Interventions
- DRUG Placebo
- OTHER immunohistochemistry staining method
- DRUG Tamoxifen Citrate
- PROCEDURE Digital mammography
- OTHER pharmacological study
Study Locations (13)
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic - Rochester
Alabama
- University of Alabama at Birmingham - Birmingham
California
- City of Hope Medical Center - Duarte
Colorado
- University of Colorado, Anschutz Medical Campus - Aurora
Illinois
- University of Chicago - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
North Carolina
- Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2010-09 |
| Est. Completion | 2028-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01196936
The ClinicalTrials.gov registry entry for NCT01196936 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT01196936 reports 13 study locations spanning 12 distinct geographic areas - top geographies include Minnesota, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT01196936 about?
NCT01196936 is a clinical study titled "Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors". Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells This phase IIb trial studies how well low-dose tamoxifen citrate works in reducing breast cancer risk in radiation-induced cancer ...
What is the current status of trial NCT01196936?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2010-09. Estimated completion is 2028-12-11.
What conditions does trial NCT01196936 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01196936?
The interventions under investigation include: Placebo (DRUG), immunohistochemistry staining method (OTHER), Tamoxifen Citrate (DRUG), Digital mammography (PROCEDURE), pharmacological study (OTHER).
Who is sponsoring clinical trial NCT01196936?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01196936 being conducted?
This trial has 13 study locations across Alabama, California, Colorado, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.